REVIEW

Imaging of thyroid carcinoma with CT and MRI: approaches to common scenarios

Jenny K. Hoang, Barton F. Branstetter IV, Andreia R. Gafton, Wai K. Lee, Christine M. Glastonbury

*Department of Radiology and Biomedical Imaging, Department of Radiology, Otolaryngology, Head and Neck Surgery, and Radiation Oncology, University of California, San Francisco, CA, USA*

Abstract
Computed tomography (CT) and magnetic resonance imaging (MRI) can play an important role in preoperative and post-treatment assessment of thyroid malignancy. The radiologist should be aware of the pathological behavior of thyroid carcinoma, and the characteristic imaging appearance of the primary tumor and metastases. This review describes the approach to imaging thyroid cancer on CT and MRI for four common scenarios: detection of the incidental thyroid nodule, evaluation of thyroid nodal metastases, presurgical imaging for invasive disease, and evaluation for recurrence in the post-treatment neck.

Keywords: Thyroid cancer; computed tomography; magnetic resonance imaging; incidental thyroid nodule.

Introduction
Although sonography is the primary imaging test for a palpable thyroid nodule or known thyroid malignancy, thyroid abnormalities are frequently first discovered on other cross-sectional modalities of computed tomography (CT) and magnetic resonance imaging (MRI). A thyroid lesion may be seen as an incidental finding, or CT and MRI may be first used for evaluation of an unknown neck mass.

This review describes four common scenarios in which CT and MR imaging of thyroid carcinoma may arise: detection of the incidental thyroid nodule (ITN), evaluation of thyroid nodal metastases, presurgical imaging for invasive disease, and evaluation for recurrence in the post-treatment neck.

Histological types and risk factors
The incidence of thyroid cancer is estimated at 37,000 per year in the United States and has more than doubled over the last 30 years. This has been largely attributed to an increased work-up of incidentally detected thyroid nodules on imaging. Most primary thyroid carcinomas are papillary (88%), follicular (8%), medullary (1%) or anaplastic (1%). These four histopathologies are the focus of this article. Other primary cancers of the thyroid such as squamous cell carcinoma (SCCa), sarcoma and lymphoma are extremely rare (combined less than 1%).

Papillary and follicular carcinomas (including Hurthle cell variant of follicular) are known as differentiated thyroid carcinomas (DTC). Both have an excellent prognosis with 10-year survival rates of greater than 95% and 85%, respectively. In particular, small papillary cancers have indolent behavior. Epidemiological studies show the absence of a survival improvement despite increased diagnosis of small thyroid cancers, and a Japanese study showed no deaths over 10 years in non-aggressive small thyroid carcinomas that did not receive treatment.

Medullary thyroid carcinoma (MTC) arises from neuroendocrine C cells in the thyroid gland that produce...
Imaging protocol

Communication with the clinician is important before performing a contrast CT scan in a patient with known thyroid malignancy. In many cases, a noncontrast study is preferred because the free iodide load of contrast medium injections interferes with iodide uptake in the thyroid for at least 6–8 weeks[9,10]. For patients with DTC, this compromises the use of diagnostic thyroid scintigraphy and radioiodine ablation for 2–6 months depending on the institution[10]. MRI contrast (gadolinium) does not interfere with iodine uptake.

CT imaging at our institutions involves multidetector acquisition from the skull base to the tracheal bifurcation with or without contrast. Multiplanar 2-mm axial, coronal and sagittal images are provided for interpretation. Our MRI protocol has a similar coverage from the skull base to the tracheal bifurcation and includes the following sequences: axial and coronal T1-weighted and fat-saturated T2-weighted images, followed by post-contrast axial and coronal T1-weighted images.

Imaging with CT and MRI

ITN on CT and MRI

With increased use of CT and MRI, ITNs or so-called thyroid incidentalomas are becoming a growing problem. ITNs are common and present in up to 1 in 6 CT studies of the neck[11–13]. The decision to report the nodule is difficult because in the absence of frank local invasion or fluorodeoxyglucose (FDG)-positron emission tomography (PET) focal uptake, there are no findings on CT and routine MRI to reliably identify the malignant lesions[14–16]. Studies have shown value in adding diffusion-weighted imaging to neck MRI because benign nodules have a higher apparent diffusion coefficient value, but the preferred modality for work-up is still ultrasonography[17,18].

Arguments against work-up of small ITNs with ultrasonography are that the malignancy rate in the incidental nodule is low, ranging from 0 to 9%[12,13,19–22] and, as discussed, the prognosis of malignancy is excellent with many patients dying with, rather than of, thyroid carcinoma[23]. Despite these favorable factors, radiologists still worry about missing malignancy. Many struggle with the balance of being cost-effective about recommending further imaging and the fear of missing a potential tumor[12].

Without guidelines for reporting ITNs on CT and MRI, previous authors have suggested extrapolating from sonographic criteria for fine-needle aspiration biopsy and using a size cut-off of 10 mm or 15 mm to triage nodules detected on CT or MRI for work-up[12,24]. The most common method for selecting a CT-detected ITN for ultrasonography is to use a 10-mm size cut-off[25]. The disadvantage of this method is that a large number of benign nodules would qualify for work-up: up to 78% of incidentally detected nodules on CT would require sonography[13]. Hoang et al.[16] recently proposed a strategy for reporting ITNs seen on cross-sectional imaging based on prioritizing subsets of patients who are more likely to have malignant nodules. Their 3-tiered system selects nodules for work-up based on nodule size but also imaging features of advanced malignant disease and young patient age. A modified version of this reporting system (Table 1) was recently applied to a single institution’s cohort of 133 CT-detected incidental nodules and the National Cancer Institute’s SEER database of thyroid carcinoma. Compared with using a 10-mm size cut-off alone, the 3-tiered risk stratification method, with a 15-mm nodule size cut-off, identified almost half the number of ITNs for work-up, but captured the same proportion of cancers; there was no difference in the high-mortality cancers missed[11].

Evaluating for nodal metastases

Papillary carcinoma and MTC are the most common thyroid cancers to metastasize to lymph nodes, whereas nodal metastases are uncommon in follicular carcinoma. Nodal masses may be the first presentation for papillary carcinoma and MTC, and CT or MRI may be performed to search for an unknown primary. In this setting, any thyroid nodule should be regarded as suspicious and warrant further evaluation with ultrasonography. The radiologist should also be aware that some thyroid primaries may not be seen on CT and MRI as they may be small, diffuse or multifocal (Figs. 1 and 2)[26].

In a patient presenting with adenopathy, the findings from a nodal mass that suggest a primary thyroid origin include cystic components (Figs. 1–3), calcification (Figs. 2 and 4), intense enhancement, or proteinaceous or hemorrhagic content appearing as hyperdensity on CT.
and T1 hyperintensity on MRI\cite{27}. It is important that cystic neck masses in young adults are not dismissed as congenital cysts, but considered SCCa or thyroid carcinoma until proven otherwise (Fig. 3).

In patients with diagnosed thyroid malignancy, nodal staging is optimal if the radiologist is cognizant of the common sites of nodal metastases. Previous studies are useful resources for the location of the nodal groups\cite{27,28}. Thyroid nodal metastases commonly occur in the central compartment (level VI) and the lateral nodal groups (levels II–IV) (Figs. 1–5)\cite{29}. The highest lymph node in the central compartment is the Delphian node or prelaryngeal lymph node (Fig. 5) and involvement of this group in papillary thyroid cancer is predictive of advanced nodal disease in that patients are nine times more likely to have lateral nodal involvement\cite{30}. Other nodal sites that should not be neglected are the lower paratracheal nodes in the superior mediastinum (level VII), and the retropharyngeal (Fig. 6) and retroesophageal groups\cite{31}.

### Table 1  The 3-tiered system of risk categories for thyroid nodules detected by CT, MRI or PET

| Category | Characteristic of incidental nodules | Suggested work-up recommendations |
|----------|-------------------------------------|-----------------------------------|
| Risk category 1: highly suspicious for malignancy | PET avid thyroid nodule | Recommend fine-needle aspiration |
| | Associated lymphadenopathy | |
| | Extrathyroid spread with or without signs of vocal cord palsy on side of nodule | |
| | Lung metastases | |
| Risk category 2: indeterminate with risk factors | High-risk history\* | Recommend ultrasonography for further characterization |
| | Demographics: female <20 years or male <35 years | |
| | Demographics: female 20–35 years | Comment that ultrasonography for characterization can be considered given the young age |
| Risk category 3: indeterminate without risk factors | >1.5 cm or substantial interval growth | Describe in the impression |
| | ≤1.5 cm | Describe in body of report only |

\*High-risk history: history of thyroid cancer in one or more first-degree relatives; history of external beam radiation as a child; exposure to ionizing radiation in childhood or adolescence; previous hemithyroidectomy with discovery of thyroid cancer, MEN2/FMTC-associated RET protooncogene mutation, calcitonin >100 pg/ml. MEN, multiple endocrine neoplasia; FMTC, familial medullary thyroid cancer.

**Figure 1** A 58-year-old man with papillary thyroid carcinoma presenting with large cystic nodal metastases and occult primary on imaging. (a) Axial enhanced CT image shows bilateral neck cystic masses, larger on the left (arrows). The thyroid had normal appearance on CT without focal lesions. The gland was also normal on sonography (not shown). (b) Coronal reformatted enhanced CT image shows multiple complex solid cystic masses in lateral nodal groups, levels II, III and IV on the left and level IV on the right (arrows). There are similar smaller cystic masses inferior to both lobes of the thyroid gland in keeping with level VI nodes (curved arrows). Fine-needle aspiration of one of the nodes revealed psammoma bodies and stained positive for thyroglobulin, which was diagnostic of papillary carcinoma. The surgical specimen from total thyroidectomy found multifocal papillary carcinomas of various sizes from 0.1 cm to 1.4 cm in the isthmus and both lobes.
The American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM staging system classifies nodal stage by site: N1a is level VI nodal disease (including pretracheal, paratracheal, and Delphian nodes), and N1b is involvement of unilateral or bilateral lateral cervical nodes, or superior mediastinal nodes. The presence of superior mediastinal nodes may preclude surgery for curative intent so CT or MRI may be indicated if there are predictors of mediastinal disease such as lateral nodes or primary tumor greater than 1.5 cm.

It is important to remember that assessment of abnormal nodal morphology is better than using size criteria for metastatic disease because up to 61% of nodal metastases may be less than 10 mm in diameter. Other special characteristics about thyroid nodal metastases are that discontinuous nodal metastases (skip metastases) occur in up to 21% of cases of MTC. Whereas nodal metastases are much less common with follicular thyroid carcinoma, local invasion and distant metastases to the bone and lung are more common (Fig. 7).

Assessing invasion for preoperative planning

With the exception of most cases of anaplastic carcinoma, the treatment of thyroid carcinoma involves total or near total thyroidectomy, central nodal resection, and possible radioiodine ablation. The management of small tumors less than 10 mm may be limited to lobectomy, but if the small tumors are multifocal, treatment still involves total thyroidectomy and radioiodine ablation. CT and MRI cannot diagnose multifocal tumor and cannot reliably determine the histology of thyroid cancer. Preoperative work-up with imaging starts with ultrasonography to detect multifocal disease and lymphadenopathy. CT and MRI are performed if local invasion is suspected.

The implication of locally invasive carcinoma may be more extensive surgery (e.g., laryngectomy), involvement of other specialty surgeons (e.g., thoracic or reconstructive plastic surgery), or a decision not to operate. Local invasion is also a key component of the AJCC/UICC tumor (T) staging (Table 2). This staging system focuses on four groups of structures: the airway and nerves centrally (including trachea, esophagus, larynx
and pharynx, and recurrent laryngeal nerve (RLN)), the
carotid arteries laterally, the prevertebral space poster-
iorly, and the mediastinum inferiorly.

MRI and CT have similar accuracy for predicting local
invasion of the esophagus, trachea/larynx and RLN. The sensitivity, specificity and accuracy of
MRI and CT from several retrospective studies are sum-
marized on Table 3. The main sign for tracheal and
esophageal invasion on both MRI and CT is a mass
contacting 180° or more of the circumference of these
organs. Other findings suggesting tracheal invasion are
deformity of the lumen, focal mucosal irregularity or
thickening, and intraluminal mass (Figs. 8 and 9). Other imaging features of RLN
invasion are signs of vocal cord dysfunction (Fig. 10) and 25% or more of the circumference of the primary
tumor abutting the capsule at the posterior portion of the
thyroid (sign of posterior extracapsular invasion).

Vascular and prevertebral space invasion are desig-
nated T4b disease (Table 2). In general, these findings
preclude the patient from curative surgery. Seo et al. found contact of thyroid tumor with 180° or more of the
circumference of the vessel to be a highly specific sign for
common carotid artery and internal jugular vein invasion
on CT (Fig. 7A). However, in another study of head
and neck tumors, this finding had low accuracy of 50%
for arterial invasion due to a high rate of false-negative
cases. The investigators found that more accurate CT
findings for arterial involvement were arterial compres-
sion/deformation or fat/fascial plane deletion (accuracy
84%) (Fig. 8). Increasing the criterion of circumfer-
tential encasement to 270° also increases the specificity;
this sign on MRI had 100% sensitivity and 88% speci-
ficity. On MRI, prevertebral musculature invasion can
be excluded if there is preservation of the retropharyngeal
fat, but determining invasion with findings of muscle T2
hyperintensity, enhancement, or contour abnormality is
less accurate (accuracy <60%).

Cross-sectional imaging has a secondary role in detect-
ing anomalous anatomy that can make surgery more
complicated or predispose structures to injury. An exam-
ple is the non-recurrent inferior laryngeal nerve
(NRILN), a variant of the inferior laryngeal nerve.
Rather than looping under the right subclavian artery
(SCA), the NRILN branches from the vagus and directly
enters the larynx. The radiologist can suggest the possi-
bility of a right NRILN when there is an aberrant right
SCA.

Figure 4 A 57-year-old man with MTC and coarsely calcified nodal metastases. Coronal reformatted unenhanced CT image shows a large coarsely calcified left level VI nodal mass. This is immediately inferior to the left lobe of the thyroid and was mistaken for a benign calcified hyperplastic thyroid nodule on initial ultrasonography before the CT. Several truly benign thyroid nodules were also found on ultrasonography leading to an incorrect diagnosis of multinodular goiter. CT showed other left level IIa and III nodal masses with coarse calcification, also representing MTC metastases (arrowheads).

Figure 5 A 24-year-old woman with metastatic papillary carcinoma including a Delphian nodal metastasis. She presented with a right neck mass. Axial enhanced CT image shows a large mass in the right lobe of the thyroid. There are heterogeneously enhancing right level IV nodal masses (arrows) and an enlarged Delphian node (arrowhead).
Figure 6  A 52-year-old woman with papillary carcinoma and a retropharyngeal metastasis. She had a history of fibromyalgia and presented with 1 year of right-sided neck pain. On clinical examination, she was found to have right neck adenopathy and an enlarged right thyroid lobe, subsequently proven to contain papillary thyroid carcinoma. A contrast-enhanced CT scan was performed before thyroid carcinoma was suspected. (a) Axial enhanced CT image shows subtle asymmetry of the prevertebral muscles (arrows). (b) The same axial enhanced CT image with narrowed window width shows a metastatic right retropharyngeal node (arrow) to be much more conspicuous. This case highlights the subtlety of retropharyngeal nodes on CT, which may be even more problematic when contrast is not given.

Figure 7  A 51-year-old woman with follicular carcinoma with venous invasion. She presented with an enlarging neck mass. (a) Axial enhanced CT image demonstrates a heterogeneously enlarged thyroid gland (arrows), displacing the trachea to the right. This was biopsied and determined to be follicular carcinoma. There was no evidence of neck adenopathy, and what resembles a node in the left neck (arrowheads) represents intravenous extension of tumor in the left internal jugular vein (IJV). (b) Coronal reformatted enhanced CT image better delineates extension of tumor in the left IJV (arrowheads).
Evaluating for recurrence in the post-treatment neck

Serum thyroglobulin level is used as a marker for recurrent or residual DTC. When increased, a neck ultrasonogram and 131I or 123I whole-body imaging are typically obtained. The latter may be negative in 50–80% of patients and represents progression with dedifferentiated thyroid cancer [44,45]. In such cases, MRI or PET/CT have a role in localizing the tumor for surgery. The outcome may still be curative provided there is complete resection of tumor tissue [46]. If the metastatic disease is too extensive, the treatment regimen may be changed to a palliative approach.

MRI can be readily performed for assessment of thyroid recurrence, even if it is not dedifferentiated, because it does not use iodinated contrast. MRI also has the ability to detect nodal disease with high protein content from colloid, thyroglobulin, and blood products (Fig. 11) [31]. If lateral and central neck dissections have been performed, it becomes even more important to carefully evaluate the retropharyngeal nodal groups [31].

PET/CT typically has limited sensitivity for detection of DTC but as the tumor dedifferentiates its tendency to take up FDG increases. The intensity of FDG uptake is correlated with progressive dedifferentiation and a more aggressive tumor, but does not always mean a worse prognosis [46]. PET/CT has 81–82% sensitivity and 64–89% specificity for detection of recurrent tumor in the setting of increased serum thyroglobulin level and negative whole-body iodine scan (Fig. 12) [45,47]. A pitfall of PET is that most thyroid nodal metastases are typically small and may be missed by the resolution of PET/CT. Aside from regional metastases, PET/CT can also detect unrecognized distant metastases in the lungs and bones.

Serum calcitonin and carcinoembryonic antigen (CEA) are markers used for detection of otherwise subclinical MTC recurrence. For MTC, FDG-PET uptake can be helpful if positive, but FDG uptake is variable.

### Table 2 AJCC TNM staging for thyroid cancer: T staging of DTC and MTC

| T stage | Size in greatest dimension | Presence of invasion |
|---------|---------------------------|---------------------|
| T1      | ≤2 cm                     | No extracapsular invasion |
| T2      | >2 cm, ≤4 cm              | No extracapsular invasion |
| T3      | >4 cm                     | OR minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues) |
| T4a     | Any size                  | Beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve |
| T4b     | Any size                  | Prevertebral fascia or encases carotid artery or mediastinal vessels |

Patients with DTC <45 years of age can only be staged as stage I or II; stage II has metastatic disease (M1). For patients with DTC ≥45 years and MTC at any age, M1 determines stage IVc.

All anaplastic carcinomas are T4a, confined to thyroid, or T4b, invasion beyond the capsule. Therefore, all are Stage IV.

### Table 3 Sensitivity, specificity and accuracy of CT and MRI for extrathyroid invasion

| Anatomical structure | CT (%) | CT criteria | MRI (%) | MRI criteria |
|----------------------|--------|-------------|--------|--------------|
| Trachea              |        |             |        | One of:      |
| Sensitivity          | 59     | ≥180° circumferential contact | 100   | ≥180° circumferential contact |
| Specificity          | 91     | Mucosal abnormality | 84    | Soft tissue signal in cartilage |
| Accuracy             | 83     | Lumen deformity | 90    | Infraluminal mass [36] |
| Esophagus            |        |             |        | One of:      |
| Sensitivity          | 29     | ≥180° circumferential contact OR | 82   | ≥180° circumferential contact |
| Specificity          | 96     | Abnormal wall or lumen | 82    | Soft tissue signal in cartilage |
| Accuracy             | 91     | Normal wall or lumen | 91    | Infraluminal mass [36] |
| Recurrent laryngeal nerve |    | 2 of the following: | 94   | Outer layer invasion [37] |
| Sensitivity          | 78     | Effaced fatty tissue in tracheoesophageal groove | 94    | Effaced fatty tissue in tracheoesophageal groove on at least one axial image [35] |
| Specificity          | 90     | ≥25% of tumor abutting posterior portion of thyroid | 82   | Effaced fatty tissue in tracheoesophageal groove |
| Accuracy             | 86     | Signs of ipsilateral vocal cord palsy | 88    | Effaced fatty tissue in tracheoesophageal groove |
| Carotid artery       |        |             |        | One of:      |
| Sensitivity          | 75     | ≥180° circumferential contact | 100   | ≥270° circumferential encasement [41] |
| Specificity          | 99     | Lumen deformity | 88    | Mucosal abnormality |
| Accuracy             | 99     | Lumen deformity | 91    | Mucosal abnormality |
| Internal jugular vein|        |             |        | One of:      |
| Sensitivity          | 33     | ≥180° circumferential contact | 100   | ≥270° circumferential encasement [41] |
| Specificity          | 99     | Mucosal abnormality | 88    | Mucosal abnormality |
| Accuracy             | 97     | Mucosal abnormality | 91    | Mucosal abnormality |
Figure 8  A 68-year-old woman with papillary thyroid carcinoma with nodal metastatic disease invading the trachea. (a) Axial T2-weighted image shows a T2 hyperintense mass in the right paratracheal region (arrow) with soft tissue signal in the right tracheal cartilage and an intraluminal mass (arrowhead). (b) Coronal T2-weighted image shows the mass encasing the right brachiocephalic artery (BCA) with loss of the fat plane. There is also a right level IV nodal metastasis (curved arrow). She was treated with radioactive iodine and tracheal stenting. Four months later she presented with massive hemoptysis. CT images at presentation showed progression of disease.

Figure 9  A 65-year-old man with locally invasive and metastatic MTC with tracheal invasion. He presented with a neck mass and had increased calcitonin levels. (a) Axial enhanced CT image shows a large left thyroid lobe mass that mildly narrows the trachea (asterisk), and abuts the esophagus (black arrow) with loss of the fat plane. The mass contacts the vertebral body (arrow), which was concerning for prevertebral space invasion. There is also a large left level IV nodal metastasis that displaces and indents the internal jugular vein (IJV) anteriorly and the common carotid artery (CCA) medially. (b) Coronal reformatted enhanced CT image shows tenting on the inner margin of the left trachea (arrow) suggesting intraluminal tumor extension. At surgery, there was frank invasion of the left trachea and prevertebral space, which precluded curative resection.
Figure 10  A 61-year-old man with anaplastic thyroid carcinoma with invasion of the recurrent laryngeal nerve. He presented with hoarseness. (a) Axial enhanced T1-weighted MRI shows a heterogeneous enhancing mass (arrowheads) in the right lobe of the thyroid. There is loss of the fat plane in the tracheoesophageal groove. The mass abuts the trachea but the mass is ≈180° around the trachea. There is posterior displacement of the esophagus (arrow), but there is no circumferential mass. (b) Axial enhanced T1-weighted MRI at the level of the true vocal cords shows a dilated right laryngeal ventricle (curved arrow) and anteromedial positioning of the right arytenoid cartilage suggesting vocal cord paralysis. At surgery there was invasion of the right recurrent laryngeal nerve, and perichondrium of the cricoid and 1st to 3rd tracheal rings without deep tracheal invasion. Biopsies of the esophagus were negative. The patient had a total thyroidectomy, followed by chemoradiotherapy. One and two years later he had resection of a right adrenal metastasis and two lung metastases, respectively.

Figure 11  A 41-year-old woman with treated papillary carcinoma and a cystic nodal recurrence. She was initially treated with thyroidectomy and a central neck dissection followed by ablative $^{131}$I therapy. Serum thyroglobulin levels were not increased on follow-up, but a palpable low neck mass was evident. (a) Axial T1-weighted MRI demonstrates a rounded hyperintense lesion (arrow) with a posterior solid nodule (arrowhead) anterior to the right trapezius muscle corresponding to level Vb. The lesion has similar signal intensity to adjacent fat. (b) Axial T2-weighted MRI shows the lesion to be T2 hyperintense (arrow) except for the solid posterior nodule (arrowhead). This was resected and found to be a predominantly cystic papillary thyroid nodal recurrence. The T1 and T2 hyperintense signal likely represents high protein content in the cyst from colloid, thyroglobulin or blood products. Intrinsically hyperintense nodal metastases can be difficult to appreciate on T1 and non-fat-saturated T2 and post-contrast sequences, especially when they are small nodal metastases. Cystic metastases may also be negative on $^{131}$I and PET imaging.
for MTC and even large metastases can be FDG negative\textsuperscript{48}. Therefore, lack of uptake should not be interpreted as absence of disease in MTC. In a study comparing FDG-PET with CT and MRI, the cross-sectional modalities detected a higher percentage of pulmonary and hepatic metastases, but FDG-PET was superior in detecting nodal metastases\textsuperscript{49}. Hence, the combination of CT with PET increases sensitivity and specificity compared with PET alone.

**Conclusion**

The radiologist should be aware of the scenarios in which thyroid malignancy can be imaged with CT and MRI and how to approach a thyroid nodule and nodal disease with these modalities. There are clinical and cross-sectional imaging findings that make an ITN more suspicious for malignancy. For known malignancy, CT and MRI are helpful for detecting extrathyroid invasion. Knowledge of the behavior and appearance of nodal metastases on CT and MRI is crucial for preoperative assessment and for evaluation of recurrent tumor.

**Conflict of interest**

C.M. Glastonbury is an investor in and consultant for Amirsys.

**References**

[1] Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US features of thyroid malignancy: pearls and pitfalls. Radiographics 2007; 27: 847–860. doi:10.1148/rg.273065038. PMid:17495296.

[2] Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167–1214. doi:10.1089/thy.2009.0110. PMid:19860577.

[3] National Cancer Institute. Surveillance Epidemiology and End Results Data 1983 to 2009. Available at: http://seer.cancer.gov/ (accessed December 2012).

[4] Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998; 83: 2638–2648. doi:10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1. PMid:9874472.

[5] Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006; 295: 2164–2167. doi:10.1001/jama.295.18.2164. PMid:16684987.

[6] Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010; 34: 28–35. doi:10.1007/s00268-00943034. PMid:20020290.

[7] Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010, xiv, 648 p.

[8] Niccoli-Sire P, Murat A, Rohmer V, et al. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 2001; 86: 3746–3753. doi:10.1210/jc.86.8.3746. PMid:11502806.

[9] Luster M, Clarke SE, Dietlein M, et al. Guidelines for radiodiery therapy of differentiated thyroid cancer. Eur J Nucl Med Mol...
van der Molen AJ, Thomsen HS, Morcos SK. Effect of iodinated contrast media on thyroid function in adults. Eur Radiol 2004; 14: 902–907. PMid:14997334.

Nguyen X. Roy Choudhury K, Lyman GH, et al. Incidental thyroid nodules on CT: comparison of two risk categorization methods for workup of nodules. AJNR Am J Neuroradiol 2013.

Yousum DM, Huang T, Loewner LA, Langlotz CP. Clinical and economic impact of incidental thyroid lesions found with CT and MR. AJNR Am J Neuroradiol 1997; 18: 1423–1428.

Yoon DY, Chang SK, Choi CS, et al. The prevalence and significance of incidental thyroid nodules identified on computed tomography. J Comput Assist Tomogr 2008; 32: 810–815. doi:10.1097/01.RCT.0000318175.37821.01 PMid:18380117.

Shie P, Cardarelli R, Sprawls K, Taur A. Systematic review: prevalence of malignant incidental thyroid nodules identified on 18F-fluorodeoxyglucose positron emission tomography. Nuc Med Commun 2009; 30: 742–748. doi:10.1097/MNM.0b013e32822e09d PMid:19561553.

Eloy JA, Brett EM, Fatterpek G, et al. The significance and management of incidental 18F-fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer. AJNR Am J Neuroradiol 2009; 30: 1431–1434. doi:10.3174/ajnr.A1559 PMid:19342543.

Hoang JK, Raduazo P, Yousum DM, Eastwood JD. What to do with incidental thyroid nodules on imaging? An approach for the radiologist. Semin Ultrasound CT MR 2012; 33: 150–157. doi:10.1053/j.sult.2011.12.004 PMid:22410363.

Razek AA, Sadek AG, Kombar OR, Elmahdy TE, Nadu N. Role of apparent diffusion coefficient values in differentiation between malignant and benign solitary thyroid nodules. AJNR Am J Neuroradiol 2008; 29: 563–568. doi:10.3174/ajnr.A0849 PMid:18039755.

Bozgeyi Z, Coskun S, Dagli AF, Ozkan Y, Sahpaz F, Oegur E. Diffusion-weighted MR imaging of thyroid nodules. Neuroradiology 2009; 51: 193–198. doi:10.1007/s00234-008-0494-3 PMid:19165474.

Bartolotta TV, Midiri M, Runza G, et al. Incidentally discovered thyroid nodules: incidence, and greyscale and colour Doppler pattern in an adult population screened by real-time compound spatial sonography. Radiol Med 2006; 111: 989–998. doi:10.1007/s11547-006-0097-1 PMid:17021683.

Brander AE, Vikinkoski VP, Nickels JI, Kivisaari LM. Importance of thyroid abnormalities detected at US screening: a 5-year follow-up. Radiology 2000; 215: 801–806. PMid:10831702.

Steel SR, Martin MJ, Mullenix PS, Azarow KS, Andersen CA. The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg 2005; 140: 981–985. doi:10.1001/archsurg.140.10.981 PMid:16230549.

Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985; 56: 531–538. doi:10.1002/1097-0142(198505)56:3<531::AID-CNCR2625060321-3.0.CO;2-3> PMid:2408737.

Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005; 237: 794–800. doi:10.1148/radiol.2373050220 PMid:16304103.

Johnson PT, Horton KM, Megibow AJ, Jeffrey RB, Fishman EK. Common incidental findings on MDCT: survey of radiologist recommendations for patient management. J Am Coll Radiol 2011; 8: 762–767. doi:10.1016/j.jacr.2011.05.012 PMid:22051458.

Shetty SK, Maher MM, Hahn PF, Halpern EF, Aquino SL. Significance of incidental thyroid lesions detected on CT: correlation among CT, sonography, and pathology. AJR Am J Roentgenol 2006; 187: 1349–1356. doi:10.2214/AJR.05.0468 PMid:17056928.

Hoang JK, Vanka J, Ludwig BJ, Glastonbury CM. Evaluation of cervical lymph nodes in head and neck cancer with CT and MRI: tips, traps, and a systematic approach. AJR Am J Roentgenol 2013; 200: W17–25. doi:10.2214/AJR.12.9860 PMid:23255768.

Som PM, Curtin HD, Mancuso AA. Imaging-based nodal classification for evaluation of neck metastatic adenopathy. AJR Am J Roentgenol 2000; 174: 837–844. doi:10.2214/ajr.174.3.1740837 PMid:10701636.
head and neck. AJR Am J Roentgenol 1998; 170: 1389–1394. doi:10.2214/ajr.170.5.9574622. PMid:9574622.

[43] Takata O, Hirokazu K, Takayoshi Y, Fumio K. Nonrecurrent inferior laryngeal nerve in patients with esophageal cancer: report of two cases. Esophagus 2007; 4: 41–45. doi:10.1007/s10388-006-0099-z.

[44] Loevner LA, Kaplan SL, Cunnane ME, Moonis G. Cross-sectional imaging of the thyroid gland. Neuroimaging Clin North Am 2008; 18: 445–461. vii. doi:10.1016/j.nic.2008.05.001.

[45] Razfar A, Branstetter BF Jr, Christopoulos A, et al. Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2010; 136: 120–125. doi:10.1001/archoto.2009.215. PMid:20157055.

[46] Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative $^{131}$I scan. J Nucl Med 2001; 42: 71–76. PMid:11197983.

[47] Esteva D, Muros MA, Llamas-Elvira JM, et al. Clinical and pathological factors related to $^{18}$F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. Ann Surg Oncol 2009; 16: 2006–2013. doi:10.1245/s10434-009-0483-8. PMid:19415387.

[48] Ong SC, Schoder H, Patel SG, et al. Diagnostic accuracy of $^{18}$F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48: 501–507. doi:10.2967/jnumed.106.036681. PMid:17401085.

[49] Szakall S Jr., Esik O, Bajzik G, et al. $^{18}$F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43: 66–71. PMid:11801705.